IVIG Dosing Regimen for ITP
For adults with immune thrombocytopenia (ITP), administer IVIG at 1 g/kg as a single dose, which may be repeated if necessary, or alternatively give 1 g/kg/day for 1-2 consecutive days. 1, 2
Standard Dosing Protocol
The modern, preferred regimen is 1 g/kg given as a one-time dose 1. This approach:
- Achieves platelet response within 24 hours in many patients 3
- Typically produces response within 2-4 days 3
- Can be repeated if the initial response is inadequate 1
The alternative regimen of 1 g/kg/day for 2 consecutive days (total dose 2 g/kg) is equally effective 3. IVIG may be discontinued after 1-2 days if adequate platelet response is achieved 3.
Why This Replaced the Old Regimen
The historical dosing of 0.4 g/kg/day for 5 consecutive days is now obsolete. The higher-dose, shorter-duration regimen (1 g/kg for 1-2 days) produces faster platelet increases within 24 hours compared to the 5-day protocol 3. Recent studies confirm response rates of 72-80% with the modern regimen 4, 5, 6.
Infusion Rate
- Initial rate: 0.01 mL/kg/min (0.5 mg/kg/min)
- Maximum rate: 0.10 mL/kg/min (5 mg/kg/min) if tolerated 7
- Infuse over several hours minimum 3
Clinical Context Matters
Emergency/Severe Bleeding
Combine IVIG with corticosteroids (prednisone or high-dose methylprednisolone) for patients with uncontrolled bleeding 3. This combination approach is appropriate for:
- Active CNS, GI, or genitourinary bleeding
- Patients requiring urgent surgical procedures
- High bleeding risk situations
First-Line Therapy
Use IVIG with corticosteroids when rapid platelet increase is required 1, 2. IVIG alone (or anti-D in appropriate patients) is reserved for situations where corticosteroids are contraindicated 1, 2.
Pregnancy
IVIG is a recommended treatment option during pregnancy (along with corticosteroids) 1, 2.
Important Safety Considerations
High-Risk Patients Require Dose/Rate Modification
For patients at risk of renal dysfunction or thrombosis, administer at the minimum dose and infusion rate practicable 7. Risk factors include:
- Advanced age (especially >65 years)
- Pre-existing renal insufficiency
- Hypercoagulable conditions
- History of thrombosis
- Cardiovascular risk factors
- Hyperviscosity
Ensure adequate hydration before administration 7.
Common Adverse Effects
- Headaches (most common, often moderate to severe) 3
- Fever, chills, fatigue
- Infusion reactions
Consider premedication with corticosteroids to reduce infusion reactions and prevent aseptic meningitis 3.
Serious But Rare Toxicities
- Renal failure and thrombosis 3
- Aseptic meningitis
- Hemolysis
- Transfusion-related acute lung injury (TRALI)
Expected Response
- Initial response rate: 70-80% of patients 3, 4, 5, 6
- Time to response: Median 1-3 days, with many responding within 24 hours 4, 5, 6
- Duration of response: Typically transient, lasting 2-4 weeks 3, though some patients maintain response for months 3
- Target: Platelet count ≥50 × 10⁹/L is achieved in approximately 80-89% of patients within 5-7 days 4, 6
Special Populations
IgA Deficiency
IVIG is contraindicated in IgA-deficient patients with anti-IgA antibodies and history of hypersensitivity 7. Use IgA-depleted preparations if IVIG is necessary 3.
Patients with CVID
For ITP patients with common variable immunodeficiency, use high-dose IVIG followed by maintenance dosing of 0.3-0.4 g/kg every 3-4 weeks 3.